{"filing":{"accession_number":"0001193125-26-249951","cik":"0001710072","ticker":"EWTX","company_name":"Edgewise Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"d24037d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1710072/000119312526249951/d24037d8k.htm"},"events":[{"id":7784,"run_id":6831,"accession_number":"0001193125-26-249951","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"This is a material asset purchase agreement where Edgewise Therapeutics is selling its neuromuscular program (including the sevasemten compound) to Servier Pharmaceuticals for $1.55 billion upfront plus up to $1.1 billion in milestone payments. The transaction constitutes a substantial disposition of a core program and is disclosed under Item 1.01 (Entry into a Material Definitive Agreement), which is the standard Item for M\u0026A activity. The magnitude ($1.55B+ in consideration) and strategic significance (sale of a major drug candidate) make this clearly material to investors.","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3119,"accession_number":"0001193125-26-249951","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This is a material asset purchase agreement where Edgewise Therapeutics is selling its neuromuscular program (including the sevasemten compound) to Servier Pharmaceuticals for $1.55 billion upfront plus up to $1.1 billion in milestone payments. The transaction constitutes a substantial disposition of a core program and is disclosed under Item 1.01 (Entry into a Material Definitive Agreement), which is the standard Item for M\u0026A activity. The magnitude ($1.55B+ in consideration) and strategic significance (sale of a major drug candidate) make this clearly material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:38:34.446182+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3119,"accession_number":"0001193125-26-249951","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This is a material asset purchase agreement where Edgewise Therapeutics is selling its neuromuscular program (including the sevasemten compound) to Servier Pharmaceuticals for $1.55 billion upfront plus up to $1.1 billion in milestone payments. The transaction constitutes a substantial disposition of a core program and is disclosed under Item 1.01 (Entry into a Material Definitive Agreement), which is the standard Item for M\u0026A activity. The magnitude ($1.55B+ in consideration) and strategic significance (sale of a major drug candidate) make this clearly material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:38:34.446182+00:00","company_name":"Edgewise Therapeutics, Inc.","ticker":"EWTX","filing_date":"2026-06-01"}]}